Graft versus host disease · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ibrutinib monotherapy Variant #01 | — | R 81 964 | 28d | ~41.3 mo | ~30.3 mo | ~2 | ~R 163 929 PFS proxy · indirect | 17 |
Ruxolitinib monotherapy Variant #06 | — | R 24 260 | — | — | — | ~2 | ~R 48 520 PFS proxy · indirect | 2 |
Prednisone monotherapy Variant #11 Partial | — | R 554 | 7d | ~2.2 mo | ~14.1 mo | ~1 | ~R 554 PFS proxy · indirect | 8 |
Cyclosporine and Prednisone Variant #01 | — | — | 56d | — | — | — | — | — |
Belumosudil monotherapy Variant #01 | — | — | 28d | — | — | — | — | — |
5 of 5 regimens shown